Supportive Care in Patients with Critical Coronavirus Disease 2019

Daniel A. Sweeney, MD*, Atul Malhotra, MD

INTRODUCTION

The mortality rate for patients with coronavirus disease 2019 (COVID-19) admitted to the intensive care unit (ICU) is approximately 30%.1,2 Since the start of the pandemic therapeutic advances, including vaccines, monoclonal antibodies, antiviral agents, and immunomodulating therapies, have resulted in fewer patients with COVID-19 being hospitalized and requiring ICU admission. However, current therapeutics have not been consistently helpful once a patient with COVID-19 progresses to the point of requiring critical care support, with only baricitinib in a placebo-controlled trial and dexamethasone in an open-label trial demonstrating benefit in patients receiving mechanical ventilation.3,4 Even vaccines, which have drastically reduced the burden of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection worldwide,
do not measurably reduce either length of stay or mortality for fully vaccinated patients compared with unvaccinated patients who are admitted to the ICU. In light of the dearth of therapeutic options for critically ill patients with COVID-19, optimization of supportive care is paramount. Although there has been great interest in expanding the application of prone ventilation to include nonintubated patients with COVID-19, current randomized trial data do not support its routine use. Rather, the pandemic experience has served to reinforce the importance of applying supportive critical care strategies that have been previously been proved to be beneficial in the management of patients with severe pneumonia and acute respiratory distress syndrome (ARDS). Accordingly, this article aims to highlight important aspects of supportive care for the critically ill patient with COVID-19, with an emphasis on a stepwise approach to the use of respiratory support for patients based on their severity of respiratory illness.

NONINVASIVE RESPIRATORY SUPPORT FOR CRITICALLY ILL PATIENTS WITH CORONAVIRUS DISEASE 2019

The need for additional respiratory support beyond low-flow oxygen therapy (<15 L/min [LPM]) is often the reason for admission to the ICU. For patients with COVID-19 who are hypoxic (oxygen saturation <92%) despite receiving low-flow oxygen, but not requiring urgent intubation, the 3 advanced respiratory support options are continuous positive airway pressure (CPAP), noninvasive positive pressure ventilation (NIPPV, also known as noninvasive ventilation [NIV] or by its trade name, “BiPAP”) or high-flow nasal cannula (HFNC). Although the data are limited, NIPPV and HFNC, both of which raised concerns for the potential to aerosolize viral particles, have not been shown to pose an increased risk of infection to health care workers who adhere to standards of personal protective equipment use. Before discussing how to choose between CPAP, BiPAP, or HFNC for a particular patient, it is worth reviewing technical aspects of these respiratory support modalities.

**Continuous Positive Airway Pressure**

CPAP uses a tight-fitting nasal or face mask and delivers oxygen to a patient with a continuous positive pressure in the system during both patient inspiration and oxygenation. As such, CPAP is not a “ventilatory” mode because it does not provide additional pressure support during inspiration. Instead, the continuous airway pressure aids in oxygenation by preventing the collapse of alveoli during expiration. The clinician sets both the fraction of inspired oxygen (FiO₂) and the continuous pressure ranging from 4 to 20 cm H₂O.

**Noninvasive Positive Pressure Ventilation**

NIVPP delivers 2 levels of pressure: an expiratory pressure (EPAP, analogous to CPAP) and an inspiratory pressure (IPAP), additional pressure provided to the patient with each breath. In addition, the clinician sets a backup respiration rate (in the event the patient does not spontaneously breathe or to ensure a certain number of breaths per minute) and the FiO₂. An example of initial NIVPP settings include IPAP = 10 cm H₂O, EPAP = 5 cm H₂O, backup respiration rate = 10 breaths per minute, and FiO₂ = 100%. Patient oxygenation can be further improved by increasing the EPAP to prevent alveolar collapse. NIVPP is a ventilatory mode. Increasing the inspiratory pressure while maintaining the same expiratory pressure (IPAP – EPAP = “delta”) will increase the patient’s tidal volume. Although hypoxemia is a cardinal feature of pneumonia, increasing the delta will serve to improve ventilation and
CO₂ removal if hypercapnia requires correction, for example, in patients with concomitant asthma or chronic obstructive pulmonary disease (COPD).

**High-Flow Nasal Cannula**

HFNC systems deliver warmed and humidified oxygen (FiO₂ = 21%–100%) via nasal cannula at flow rates ranging from greater than or equal to 15 to 60 LPM. Typical HFNC settings are FiO₂ between 50% and 100% and a flow rate between 20 and 60 LPM. Both FiO₂ and flow rates are adjusted to improve a patient’s oxygen saturation, because increasing the flow rate above the patient’s intrinsic minute ventilation prevents entrainment of room air and thus ensures that the patient is receiving the set FiO₂; moreover, high flow rates provide a modest amount of end expiratory pressure that may further improve oxygenation by recruiting more alveoli. The flow rate can also be increased to relieve dyspnea and tachypnea, because HFNC serves to reduce anatomic dead space, thus reducing the work of breathing and aiding in CO₂ clearance.

**Choosing Between Continuous Positive Airway, Noninvasive Positive Pressure Ventilation, and High-Flow Nasal Cannula Therapies for the Treatment of Patients with Coronavirus Disease 2019**

Before the SARS-CoV-2 pandemic, the use of NIVPP and HFNC for the treatment of pneumonia was supported by limited clinical trial data. In a study comparing the 2 modalities for the treatment of hypoxic respiratory failure (254 of 310 patients or 82% of trial participants with pneumonia), HFNC was associated with a greater number of ventilator-free days (P = .02) and a lower 90-day mortality rate (P = 0.006).

For the treatment of patients with COVID-19, HFNC (vs low-flow oxygen therapy) has been shown in a retrospective study (n = 379) and in a randomized controlled trial (n = 220) to reduce the need for endotracheal intubation, but not impact mortality. However, unlike the prepandemic experience, NIVPP may be superior to HFNC for the treatment of patients with COVID-19. In the Helmet Noninvasive Ventilation versus High-flow Oxygen Therapy in Acute Hypoxemic Respiratory Failure (HENIVOT) trial (n = 109), patients receiving NIPPV via a helmet device, compared with patients receiving HFNC therapy, were less likely to require mechanical ventilation (a secondary study outcome, 30% vs 51%, P = .03), although there was no difference in the number of days free of respiratory support (the primary study outcome). Also, in the RECOVERY-RS trial (n = 1273), patients treated with CPAP compared with HFNC were less likely to reach the combined end point of endotracheal intubation or death within 30 days (36.3% vs 44.4%, P = .03), but this difference was due almost entirely to differences in intubation rates (33.4% vs 41.3%; odd ratio [OR], 0.71 [0.53–0.96]) and not mortality (16.7% vs 19.2%; OR, 0.84 [0.58–1.23]). It should be noted that device intolerance (5.8% vs 0.7% of participants), adverse events (34.2% vs 20.6% of participants), and serious adverse events (1.8% vs 0% of participants), including pneumothoraces and vomiting requiring emergent intubation, were more common in patients receiving CPAP, compared with patients receiving HFNC.

Based entirely on prepandemic data, both the Surviving Sepsis Campaign and the National Institutes of Health (NIH) COVID-19 Treatment Guidelines recommend HFNC over NIVPP (and do not comment on CPAP) for the treatment of patients with hypoxic respiratory therapy despite low-flow oxygen therapy. The authors maintain that there is equipoise regarding whether 1 noninvasive respiratory support strategy is superior for the treatment of patients with COVID-19. And considering the evidence supporting both modalities, the authors recommend that choice of an NIV strategy should be based on comorbidities, patient tolerance, and institutional norms. For example,
CPAP or NIVPP may be preferable to HFNC for patients with COVID-19 and either congestive heart failure or COPD. On the other hand, patients who find NIVPP or CPAP uncomfortable are better suited for treatment with HFNC. Finally, institutional experience and resources must be considered. Over the course of the pandemic many health care systems have developed familiarity and expertise with mostly treating patients with HFNC, CPAP, or NIVPP. Pending the results of the ongoing RENOVATE study (NCT03643939) or future trials, the authors see no reason for these practice patterns to change.17

PRONING IN NONINTUBATED PATIENTS WITH CORONAVIRUS DISEASE 2019

Proning in the nonintubated (PINI) refers to the strategy of having hospitalized, nonintubated patients with hypoxic respiratory failure resting in the prone rather than the supine position for extended periods. This strategy is sometimes referred to as “awake” prone ventilation, even though this term is a misnomer because intubated patients could clearly be awake or sedated or asleep whether prone or not; similarly nonintubated patients could be awake or asleep. The proposed mechanisms of benefit of prone ventilation have been best studied for the treatment of intubated patients with ARDS before the SARS-CoV-2 pandemic (see section, “Prone ventilation for intubated patients”). Prepandemic, PINI investigations were limited to case series.18 A meta-analysis performed by Li and colleagues19 of 10 clinical trials (n = 1985 patients; in actuality 8 trials were analyzed because 2 trials had no events in either arm) involving patients with COVID-19 receiving PINI compared with supine position ventilation showed a reduction in the need for intubation (risk ratio [RR], 0.84; 95% confidence interval [CI], 0.72–0.97), but did not impact mortality (RR, 1.0; 95% CI, 0.70–1.44). Meta-regression analysis further revealed that PINI only reduced the need for intubation among patients receiving NIV modalities or being treated in the ICU. It should also be noted that the results of this meta-analysis are entirely due to results of a meta-trial (consisting of 6 national, randomized open-label trials) authored by Ehrmann and colleagues20 (n = 1121), and more specifically patients enrolled in 1 particular national trial (n = 430) who had very different baseline characteristics and were managed differently than patients enrolled at other sites.21 When the meta-analysis performed by Li and colleagues19 is repeated excluding this national trial and incorporating the results of a more recent randomized trial performed by Alhazzani and colleagues22 (n = 400), there is no benefit of PINI on intubation rates (RR, 0.89; 95% CI, 0.77–1.03) (Fig. 1). Further complicating the interpretation of PINI clinical studies is that the duration of prone positioning varied across clinical trials. In a more recent prospective, multicenter cohort study of 335 patients in the ICU receiving HFNC (187 with PINI, 148 with nonprone positioning) showed that 6 hours or more of PINI reduced the rate of endotracheal intubation and that 8 hours or more of PINI reduced the risk of hospital mortality.23 This result makes intuitive sense because the only randomized trial to show a mortality benefit of prone positioning in patients with ARDS receiving mechanical ventilations required that patients receive 16 hours of prone ventilation.24 On the other hand, rather than a dose response, duration of PINI may actually represent a confounder whereby patients who can tolerate longer sessions of PINI are less severely ill. At present, the NIH COVID-19 Treatment Guidelines recommend a trial of PINI for patient with hypoxemia requiring HFNC and for whom endotracheal intubation is not indicated.16 Although it is unlikely that PINI is harmful, the benefit of this therapy is not established. If PINI is administered to a patient receiving CPAP, HFNC, or NIVPP the authors suggest that the duration of therapy be extended, ideally lasting 8 hours or more a day.
Clinical judgment should inform the decision to intubate and initiate mechanical ventilation

Early in the pandemic, many health care systems adopted a strategy of early intubation of patients with COVID-19. The rationale for this approach was based on 2 concerns: fear of aerosolizing SARS-CoV-2 with NIV (both NIVPP and HFNC) leading to hospital-acquired COVID-19 and the theoretic risk of patient self-inflicted lung injury. The risk of NIV leading to hospital-acquired COVID-19 is not supported by 2 clinical studies. And analysis of 245 patients in 11 ICUs showed that early intubation (defined as occurring during the first 2 calendar days of their ICU stay) was associated with increased risk of secondary infection and an increased 60-day mortality risk (hazard ratio [HR], 1.74; 95% CI, 1.07–2.83). Traditionally, clinical data guide the decision to initiate mechanical ventilation in a patient with pneumonia, but clinical judgment dictates the ultimate decision. The authors endorse the use of clinical judgment, rather than an early intubation policy or protocol, when deciding when to intubate a patient with COVID-19.

Patients with coronavirus disease 2019 receiving mechanical ventilation: treating acute respiratory distress syndrome

ARDS is diagnosed when a patient has acute respiratory failure, a PaO₂:FiO₂ ratio less than 300 mm Hg, and chest radiography showing bilateral infiltrates in the absence of congestive heart failure. Patients with COVID-19 who clinically deteriorate and require mechanical ventilation almost certainly have ARDS and should be treated with previously proven strategies for patients with non-COVID-19 ARDS. In general, ventilator strategies to support patients with ARDS are designed to minimize the so-called ventilator-induced lung injury caused by the overdistension of ventilated lung units (ie, volutrauma) and the repetitive opening and closing of alveoli during the respiratory cycle (ie, atelectrauma). Since the start of the pandemic there have been no compelling data suggesting that patients with ARDS secondary to SARS-CoV-2...
infection should be treated differently than those with prepandemic ARDS in terms of mechanical ventilatory support.

**Low Tidal Volume Mechanical Ventilation**

In a landmark trial, a low tidal volume (6 mL tidal volume/kg ideal body weight) was shown to reduce mortality compared with a high tidal volume (12 mL tidal volume/kg ideal body weight) for the treatment of ARDS.\(^3\) Thus, 6 mL/kg has become the default tidal volume setting for patients with ARDS; however, clinicians should be mindful to try and minimize the plateau pressure (measured during an inspiratory pause, it is an estimate of the mean alveolar pressure) and driving pressures (computed as the plateau pressure minus positive end expiratory pressure).\(^3\),\(^4\) It is generally accepted that the plateau pressure should ideally be less than 32 mm H\(_2\)O and that driving pressure should be less than 15 cm H\(_2\)O.\(^3\),\(^4\),\(^5\)

**Prone Ventilation for Intubated Patients**

Prone ventilation has a multitude of beneficial effects on the pulmonary system in ARDS, including recruitment of alveoli, improvement in ventilation and perfusion, and lung compliance.\(^3\),\(^6\) The PROSEVA study, a multicenter randomized controlled trial involving 466 patients with severe ARDS demonstrated that prone ventilation for 16 h/d compared with ventilation in the supine position improved 28-day mortality (16% vs 32.8%, \(P < .001\)).\(^2\) It is important to note that a subsequent meta-analysis showed that the mortality benefit of prone ventilation for the treatment of ARDS was only detectable when patients were concomitantly receiving low tidal volume ventilation.\(^3\) Thus, patients with ARDS are best treated with low tidal volume ventilation, while simultaneously receiving prone ventilation.

**Paralysis**

Chemical paralysis may have a role in ensuring that an individual patient is synchronous with the ventilator and safely maintained in the prone position; however, the routine use of neuromuscular blocking agents has not been consistently shown to improve outcomes in the treatment of patients with ARDS. Paralysis was unlikely to have affected the results of the PROSEVA trial because patients in both study arms were similarly treated with neuromuscular blocking agents (91% of patients receiving prone ventilation and 82% of supine patients). And whereas a study by Papazian and colleagues\(^3\) (\(n = 340\)) showed that a 48-hour course of a continuous infusion of a neuromuscular blocking agent increased survival among intubated patients with ARDS, a subsequent, larger trial (\(n = 1006\)) by Moss and colleagues was stopped at the second interim analysis due to futility.\(^3\) Thus, use of paralytics should be individualized in ARDS rather than given routinely.\(^4\)

**Extracorporeal Membrane Oxygenation as a Rescue Therapy**

Despite the use of low tidal volume and prone positioning, patients with ARDS remain susceptible to ventilator-induced lung injury, refractory hypoxemia, and/or refractory hypercapnia. With extracorporeal membrane oxygenation (ECMO), blood is removed from the patient via a large venous catheter, pumped through an extracorporeal membrane in which carbon dioxide is removed and oxygen is delivered, and returned via another large catheter to the right atrium. Patients receiving ECMO therapy are placed on minimal mechanical ventilatory settings eliminating any ventilator-induced lung injury with the hope that lung function will recover over time. Although simple in concept, the actual delivery of ECMO and ECMO-related care requires expertise, costly resources, and is associated with a host of risks and potential complications.
for an already critically ill patient. Before the SARS-CoV-2 pandemic, in 2 randomized controlled trials, ECMO was not shown to be superior to conventional respiratory care for the treatment of patients with ARDS. The Conventional Ventilatory Support versus Extracorporeal Membrane Oxygenation for Severe Adult Respiratory Failure (CESAR) trial (n = 180) was particularly interesting because it showed that patients with ARDS who were transferred to a tertiary center specializing in ECMO experienced a 16% survival benefit without severe disability. However, the relative improvement in outcome may have been due to better general care provided at a center of excellence because only 75% of patients in the study arm received ECMO.

Our current understanding of the effectiveness of ECMO for the treatment of ARDS secondary to SARS-CoV-2 is limited in the absence of randomized controlled clinical trials. Retrospective data from one study showed that patients with COVID-19 who were treated with ECMO had an estimated 60-day mortality of 31%, which is similar to ECMO-treated patients before the start of the pandemic. In a subsequent, larger trial (n = 4812) that included patients from later in the pandemic, the investigators describe a mortality rate for patients with COVID-19 treated with ECMO of greater than 50%. Possibly the most compelling evidence supporting the use of ECMO in the treatment of COVID-19 can be found in a study performed by Gannon and colleagues that compared the mortality rates of 35 patients who were accepted for transfer by a tertiary center and treated with ECMO, versus 55 patients who were also deemed to be eligible candidates for treatment, but because of hospital capacity strain were not transferred to the tertiary center and subsequently did not receive ECMO. The in-hospital mortality rate for those patients who underwent ECMO was 42.9%, versus 89.1% for those patients who were unable to receive ECMO (adjusted HR, 0.23; 95% CI, 0.12–0.43; \( P < .001 \)). However, the findings of this small, retrospective study must be interpreted cautiously in the context of a health system that may have been overwhelmed during the pandemic.

The authors recommend that patients with COVID-19 who are intubated and failing standard ARDS respiratory supportive strategies be referred for ECMO early in their clinical course especially because determining eligibility varies across centers. Most ECMO programs evaluate patients based on expert opinion in conjunction with established criteria that takes into consideration patient age, body mass index, duration of mechanical ventilation, comorbidities (neurologic function specifically), and extrapulmonary organ dysfunction. The authors further urge clinicians taking care of patients with COVID-19 to engage preferentially with high-volume ECMO centers, because programs with less experience are more likely to have higher mortality rates.

**GENERAL CRITICAL CARE SUPPORTIVE CARE**

The experience of the SARS-CoV-2 pandemic has served to reinforce the importance of many established supportive measures used to treat all critically ill patients.

**Anticoagulation**

Rates of deep venous thromboembolism and pulmonary embolism among critically ill patients with COVID-19 are comparable to those among critically ill patients without COVID-19. Moreover, a large (n = 1098) open-label adaptive clinical trial, in which critically ill patients with COVID-19 were randomized to either therapeutic-dose anticoagulation with heparin or pharmacologic thromboprophylaxis, was stopped early for futility. Although not statistically significant, major bleeding occurred more often in patients assigned to receive therapeutic dose anticoagulation compared with patients who were treated with usual care pharmacologic thromboprophylaxis. In light
of these data, the authors agree with the NIH COVID-19 Treatment Guidelines recom-
mending pharmacologic thromboprophylaxis and not routine therapeutic-dose anti-
coagulation for critically ill patients with COVID-19 (NIH).  

**Fluid Management**

There are inherent risks for critically ill patients who are either under or over fluid resus-
citated. To date, there are no randomized clinical trials comparing different fluid man-
agement strategies for critically ill patients with COVID-19. For the treatment of non-
COVID-19-related ARDS, conservative rather than liberal fluid management strategy
was shown to increase the number of ventilator-free days (14.6 vs 12.1, \( P < .0001 \))
(a secondary study outcome) albeit without any mortality benefit (the primary study
outcome). Considering respiratory failure is the cause or is present in more than
80% of patients who die of COVID-19, the authors recommend a conservative fluid
strategy for patients with COVID-19 receiving mechanical ventilation. Estimating
the fluid status of a critically ill patient can be challenging; besides daily weight and
fluid balance measures, point-of-care ultrasonography can be a useful adjunct to
aid in guiding diuretic or fluid resuscitation decisions for the critically ill patient with
COVID-19.

**Minimizing Risk Factors for Delirium**

Unfortunately, critically ill patients with COVID-19 have been at high risk for developing
delirium, with a reported incidence of greater than 50%. In part, this finding may
represent an unintended consequence of both the supportive care measures (eg, the
frequent use of deep sedation in conjunction with paralytic agents) and hospital infec-
tion prevention policies aimed at protecting both health care works and family mem-
ers and friends of patients. As with all critically ill patients, clinicians should screen all
mechanically ventilated patients for delirium using a validated tool such as the The
Confusion Assessment method for the ICU (CAM-ICU). Limiting the use of seda-
tive/anxiolytics, especially benzodiazepines, has been the cornerstone of minimizing
delirium in the ICU. For example, it may not be necessary to administer neuromus-
cular blocking agents (and therefore concomitant high-dose sedatives) when patients
are undergoing prone ventilation. As previously described, therapeutic paralysis has
not been shown to be definitively beneficial in the treatment of patients with ARDS
in the prepandemic era; likewise, there are no clinical trials in patients with COVID-
19 supporting the routine use of neuromuscular blockade. In an observational study
of 156 patients, similar improvement in PaO2: FiO2 and O2Sat: FiO2 ratios were noted
postinitiation of prone ventilation in patients being treated with and without paralysis.
Furthermore, there were no adverse events associated with prone positioning performed
without neuromuscular blockade. Restrictive hospital visitation policies insti-
tuted during the pandemic may also have added to the overall burden of delirium
experienced by critically ill patients. Although not consistent, there is prepandemic ev-
dence to suggest that flexible and extended visiting hours can lower the incidence of
delirium and anxiety among critically ill patients. Performed during the pandemic, a
study comparing rates of delirium among patients with COVID-19 before and after the
implementation of an ICU visitor ban did not show a significant increase in the overall
incidence of delirium (27.4% vs 30.9%, respectively, \( P = .162 \)); however, a restrictive
visitor policy was associated with an increase of hyperactive and mixed subgroups of
delirium and high anxiety levels. Thus, evolving hospital visitor policies designed to
continue to prevent hospital transmission of SARS-CoV-2 should be tempered by the
potential importance of patient-visitor interactions.
SUMMARY

The early adoption of supportive care strategies for the management of ARDS, developed during the pre-pandemic era, may have been responsible for the improvement in critical care outcomes noted during the early phase (March to May, 2020) of the pandemic. Anecdotally, those of us who have taken care of critically ill patients throughout the pandemic have marveled at how proficient ICU teams of nurses and respiratory therapists have become at routinely repositioning patients with COVID-19, some of whom have chest tubes and are simultaneously receiving continuous renal replacement therapy. In addition to prone ventilation and adherence to low tidal volume ventilation, the expansive use of other measures such as NPPV, and HFNC, have the potential to reduce the need for intubation, if not possibly mortality, for critically ill patients with COVID-19. And although PINI is intriguing, its clinical benefit for patients with COVID-19 has not been established; whether longer durations of therapy (>8 hours) could be beneficial remains to be proven. Finally, the experience of the pandemic has also resulted in recognition of the importance of providing quality critical adjunctive therapies such as deep vein thrombosis prophylaxis, attention to fluid management, and minimizing sedation and neuromuscular blockade for the purpose of reducing the risk of delirium. Despite these early advances, mortality rates among critically ill patients with COVID-19 are largely unchanged over the later phases of the pandemic.\textsuperscript{60,61} Although the development of therapeutics to treat patients with severe disease specifically needs to be the primary strategy, supportive care—either by expanding the use of current strategies or developing new approaches—can serve an adjunctive role to improve clinical outcomes for critically ill patients with COVID-19.

CLINICS CARE POINTS

- Lung size does not change with either weight loss or weight gain. Ideal body weight and not actual body weight in kilograms should be used when choosing a low tidal volume for the treatment of mechanically ventilated patients with COVID-19 and ARDS.
- The nomenclature of respiratory supportive care is inherently confusing. NIV, NIPPV, bilevel, and BiPAP (a trade name) are synonymous and describe a system that uses 2 different pressures—IPAP and EPAP. CPAP as the name implies delivers one continuous pressure. HFNC delivers oxygen flow rates ranging from greater than or equal to 15 to 60 LPM as opposed to low-flow or nasal cannula oxygen, which delivers oxygen from 1 to 14 LPM.
- For patients receiving HFNC, the FiO\textsubscript{2} should be titrated based on the patient’s pulse oximetry, whereas the flow rate should be titrated based on the clinical assessment of the patient including presence of dyspnea and breathing pattern.
- Not all patients with COVID-19 and ARDS who are intubated and receiving prone ventilation require chemical paralysis; rather, the decision to administer neuromuscular blocking agents should be individualized based on patient safety and ability to maintain synchrony with the ventilator.
- Basic tenants of supportive critical care established before the pandemic remain relevant for the management of patients with severe COVID-19

DISCLOSURE

D.A. Sweeney has nothing to declare. A. Malhotra is funded by the National Institutes of Health. He reports income related to medical education from Livanova, Jazz,
Equillium, and Corvus, unrelated to the content of this manuscript. ResMed provided a philanthropic donation to UC San Diego.

REFERENCES


